Insider · CIK 0001106519
David N Gill
Files at EOLS (Evolus, Inc.), YMAB (Y-mAbs Therapeutics, Inc.). First filing -, latest -.
David N Gill files SEC Form 4 as director at EOLS (Evolus, Inc.), and also at YMAB (Y-mAbs Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David N Gill has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 15 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 17, 2026 | EOLS Evolus, Inc. | AGrant or award Common Stock | +45,559 | $0.00 | $0 | 86,887 | Feb 19, 2026 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Common Stock | -5,825 | $8.60 | $50k | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Common Stock | -25,080 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -24,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -11,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -16,000 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -13,950 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -14,545 | - | - | 0 | Sep 18, 2025 |
| Sep 16, 2025 | YMAB Y-mAbs Therapeutics, Inc. | DDisposition to issuer Employee Stock Option (right to buy)derivative | -33,450 | - | - | 0 | Sep 18, 2025 |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Common Stock | +25,080 | $0.00 | $0 | 30,905 | Jul 2, 2025 |
| Jun 30, 2025 | YMAB Y-mAbs Therapeutics, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +33,450 | $0.00 | $0 | 33,450 | Jul 2, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Common Stock | +7,364 | $0.00 | $0 | 41,328 | Mar 11, 2025 |
| Mar 7, 2025 | EOLS Evolus, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +11,146 | $0.00 | $0 | 11,146 | Mar 11, 2025 |
Questions about David N Gill
Answered from the filings on this page, as of the latest one.
Is David N Gill buying or selling?
David N Gill has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David N Gill's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David N Gill has 0.
Where does David N Gill file Form 4?
David N Gill has filed Form 4 at EOLS (Evolus, Inc.); YMAB (Y-mAbs Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.